Get started
Author

Ahmet Yildirim

ORCID: 0009-0006-2542-3714
Observed ORCID: 0009-0006-2542-3714
OpenAlex ID: A5031323636
Real-world evidences on adjuvant Pembrolizumab for renal cell carcinoma: results from the multicenter real-world ARON-1 study
2025 · Ray Manneh Kopp, Francesco Massari, et al. · Cancer Immunology Immunotherapy · 10
PDF
Association of baseline inflammatory biomarkers and clinical outcomes in patients with advanced renal cell carcinoma treated with immune checkpoint inhibitors
2025 · Ahmet Yildirim, Mengting Wei, et al. · Therapeutic Advances in Medical Oncology · 9
Immune-based Combinations in Intermediate-/Poor-risk Patients with Non–clear Cell Renal Cell Carcinoma: Results from the ARON-1 Study
2025 · Francesco Massari, Veronica Mollica, et al. · European Urology Focus · 7
Sarcomatoid Differentiation in Renal Cell Carcinoma: Clinical and Pathologic Heterogeneity and Outcomes With Immune Checkpoint Inhibitors—Data From the ARON-1 Study
2025 · Francesco Massari, Matteo Rosellini, et al. · JCO Global Oncology · 4
Recent progress in non-clear cell renal cell carcinoma: biology and therapeutic strategies
2025 · Ahmet Yildirim, Marcus W. Moses, et al. · Therapeutic Advances in Medical Oncology · 4
Body composition metrics and clinical outcomes for patients with metastatic castration-resistant prostate cancer (mCRPC) treated with lutetium-177–PSMA-617.
2026 · Margo Gerke, Angelo Marra, et al. · Journal of Clinical Oncology · 1
Real-world analysis of efficacy and safety of biweekly gemcitabine and docetaxel (GEMDOC) in heavily pretreated metastatic castration-resistant prostate cancer.
2025 · Jordan Alana Ciuro, Ahmet Yildirim, et al. · Journal of Clinical Oncology · 1
PDF
Efficacy and Safety of Every Other Week Gemcitabine and Docetaxel (GEMDOC) in Heavily Pretreated Metastatic Castration Resistant Prostate Cancer: A Retrospective Real-world Analysis
2026 · Jordan Ciuro, Ahmet Yildirim, et al. · Clinical Genitourinary Cancer
Contemporary Validation of the Renal Cell Carcinoma Inflammatory Score for Preoperative Prognostication in Nonmetastatic Renal Cell Carcinoma
2026 · Adam Braunschweig, Gabriel Ekene Agu, et al. · Urology Practice
Ip08-23 Radio-pathomic Features Associated With Response to Neoadjuvant Cabozantinib in Locally Advanced Renal Cell Carcinoma
2026 · William Luke, Liping Li, et al. · The Journal of Urology
Long-term efficacy and patient experience with neoadjuvant cabozantinib for locally advanced renal cell carcinoma.
2026 · Mehmet Asim Bilen, Ahmet Yildirim, et al. · Journal of Clinical Oncology
PDF
An increase in splenic volume after first-line immunotherapy is associated with worse PFS in patients with metastatic renal cell carcinoma
2026 · Gregory Palmateer, Ahmet Yildirim, et al. · The Oncologist
REFINE: a database of linked clinical data and genomic biomarkers in renal cell carcinoma patients receiving immunotherapy-based treatment regimens
2025 · Jeffrey Zhong, Albert Jang, et al. · The Oncologist
PDF
Works count: 13
Citation count: 36
H-index: 4
I10-index: 1
Year
Topic
Type